Skip to main content
. Author manuscript; available in PMC: 2017 Nov 8.
Published in final edited form as: Oncogene. 2017 May 8;36(25):3629–3639. doi: 10.1038/onc.2017.123

Figure 1. The gain of MCM8 gene copy in the genome of prostate cancer.

Figure 1

(A) Status of MCM8 gain in organ donor prostate (OD), benign prostate tissue adjacent to cancer (AT), prostate cancer (T). T samples were subdivided into cancers that have no recurrence for at least 5 years after radical prostatectomy (Tnone), cancers that produced recurrences with PSADT≥14 months (Tslow), and cancers that produced recurrences with PSADT≤4 months (Tfast). The gain of MCM8 was determined when copy of MCM8 was estimated to be ≥3 copies per genome relative to β-actin. (B) Representative images of fluorescence in-situ hybridization (FISH) using BAC probes corresponding to MCM8 genome sequence and centromere of chromosome 20. BAC probe for MCM8 was labeled with spectrum orange, while probe for centromere of chromosome 20 was labeled with spectrum green. (C) Prostate cancer samples with MCM8 gain status based on FISH results. (D) Kaplan-Meier analysis of prostate cancer based on the status of MCM8 gain. The analysis was plotted based on the combined results of qPCR and FISH obtained from (A) and (C).